Johan Heemskerk


Prof. Johan Heemskerk graduated in Biology and Chemistry at Radboud University Nijmegen. At the same university, he performed doctoral research on the biosynthesis of plant lipids, with post-doctoral projects at the universities of Hamburg, Helsinki and Cambridge (UK). In 1986, he moved to Maastricht University, with positions at the Departments of Human Biology and Biochemistry. He is a recipient of the BACH-ISTH award for contributions to hemostasis. He participates in the following international consortia: European Platelet Network (EUPLAN); BRIDGE-UK, Horizon 2020 TAPAS and TICARDIO, Interreg EMR PolyValve.

Since 2000, he is a Principal Investigator at CARIM, where he studies signal transduction processes and cell-cell communication in blood cells in relation to hemostasis, thrombosis, atherosclerosis, vascular biology and nutrition. Main topics in his programme are the biochemical, cell-biological and physiological regulation of platelet-dependent coagulation and the importance of this process for thrombus formation, stability and embolism. His research encompasses experimental and intervention studies with blood cells from both human and animal sources, with an emphasis on flow-dependent perfusion models using microfluidics. Within consortia, his laboratory establishes platelet proteomes in mice, healthy subjects and defined patients.

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room: H4.308

  • 2020
    • Veninga, A., De Simone, I., Heemskerk, J. W. M., Ten Cate, H., & van der Meijden, P. E. J. (2020). Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica-the Hematology Journal, 105(8), 2020-2031.
    • Nagy, M., Perrella, G., Dalby, A., Becerra, M. F., Quintanilla, L. G., Pike, J. A., Morgan, N., Gardiner, E. E., Heemskerk, J. W. M., Azocar, L., Miquel, J. F., Mezzano, D., & Watson, S. P. (2020). Flow studies on human GPVI-deficient blood under coagulating and noncoagulating conditions. Blood advances, 4(13), 2953-2961.
    • Shi, C., Kim, T., Steiger, S., Mulay, S. R., Klinkhammer, B. M., Baeuerle, T., Melica, M. E., Romagnani, P., Moeckel, D., Baues, M., Yang, L., Brouns, S. L. N., Heemskerk, J. W. M., Braun, A., Lammers, T., Boor, P., & Anders, H-J. (2020). Crystal Clots as Therapeutic Target in Cholesterol Crystal Embolism. Circulation Research, 126(8), E37-E52.
    • Brouns, S. L. N., Provenzale, I., van Geffen, J. P., van der Meijden, P. E. J., & Heemskerk, J. W. M. (2020). Localized endothelial-based control of platelet aggregation and coagulation under flow: A proof-of-principle vessel-on-a-chip study. Journal of Thrombosis and Haemostasis, 18(4), 931-941.
    • Sternkopf, M., Nagy, M., Baaten, C. C. F. M. J., Kuijpers, M. J. E., Tullemans, B. M. E., Wirth, J., Theelen, W., Mastenbroek, T. G., Lehrke, M., Winnerling, B., Baerts, L., Marx, N., De Meester, I., Doring, Y., Cosemans, J. M. E. M., Daiber, A., Steven, S., Jankowski, J., Heemskerk, J. W. M., & Noels, H. (2020). Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions. Arteriosclerosis Thrombosis and Vascular Biology, 40(3), E65-E77.
    • Onselaer, M-B., Nagy, M., Pallini, C., Pike, J. A., Perrella, G., Quintanilla, L. G., Eble, J. A., Poulter, N. S., Heemskerk, J. W. M., & Watson, S. P. (2020). Comparison of the GPVI inhibitors losartan and honokiol. Platelets, 31(2), 187-197.
  • 2019
    • Provenzale, I., Brouns, S. L. N., van der Meijden, P. E. J., Swieringa, F., & Heemskerk, J. W. M. (2019). Whole Blood Based Multiparameter Assessment of Thrombus Formation in Standard Microfluidic Devices to Proxy In Vivo Haemostasis and Thrombosis. Micromachines, 10(11), [787].
    • Coppin, L., Najimi, M., Bodart, J., Rouchon, M-S., van der Smissen, P., Eeckhoudt, S., Dahlqvist, G., Castanares-Zapatero, D., Komuta, M., Brouns, S. L., Baaten, C. C., Heemskerk, J. W. M., Horman, S., Belmonte, N., Sokal, E., & Stephenne, X. (2019). Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies. Cells, 8(8), [846].
    • Nagy, M., van Geffen, J. P., Stegner, D., Adams, D. J., Braun, A., de Witt, S. M., Elvers, M., Geer, M. J., Kuijpers, M. J. E., Kunzelmann, K., Mori, J., Oury, C., Pircher, J., Pleines, I., Poole, A. W., Senis, Y. A., Verdoold, R., Weber, C., Nieswandt, B., ... Baaten, C. C. F. M. J. (2019). Comparative Analysis of Microfluidics Thrombus Formation in Multiple Genetically Modified Mice: Link to Thrombosis and Hemostasis. Frontiers in cardiovascular medicine, 6, [99].
    • Govers-Riemslag, J. W. P., Konings, J., Cosemans, J. M. E. M., van Geffen, J. P., de Laat, B., Heemskerk, J. W. M., Dargaud, Y., & Ten Cate, H. (2019). Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis. TH open : companion journal to thrombosis and haemostasis, 3(3), e273-e285.